The in vitro activities of azlocillin and cefotaxime in combination and of azlocillin and tobramycin in combination against 100 blood isolates and 50 multidrug-resistant isolates were compared. With both combinations, antibacterial spectrums were complementary. Although synergy against individual strains was infrequently observed (except for azlocillin-cefotaxime against Streptococcus faecalis and azlocillin-tobramycin against Pseudomonas aeruginosa), 97% of blood isolates and 76% of multidrug-resistant isolates were susceptible to azlocillin-cefotaxime, and 94% of blood isolates and 36% of multidrug-resistant isolates were susceptible to azlocillin-tobramycin.
Penicillin-aminoglycoside and cephalosporinaminoglycoside antibiotic combinations have broad antibacterial spectrums, are frequently synergistic in vitro, and are commonly used to treat a variety of serious bacterial infections (9) . To avoid aminoglycoside toxicity, penicillincephalosporin combinations have also been used, but results using early derivatives have not been optimal (2) . In recent years, new penicillins and cephalosporins which have greater potencies and spectrums of activity than their prototypes have been developed (4, 7) . Therefore, a reexamination of the potential for using penicillin-cephalosporin combinations as alternatives to 3-lactam-aminoglycoside combinations for treating certain types of infections seems appropriate.
In this study, we compared the in vitro activity of azlocillin (a new antipseudomonal penicillin) and cefotaxime (a third generation of cephalosporin) in combination with the activity of azlocillin and tobramycin ( (6) . Antibiotics were considered synergistic when there was a fourfold or greater reduction in MICs of both drugs in a combination compared with MICs of individual drugs, antagonistic when there was a fourfold or greater increase in MICs of both drugs or when the addition of an inactive antibiotic to an active antibiotic increased the MIC of the latter by fourfold or more, and indifferent when the results were intermediate. Results were considered indeterminate if the endpoints were not in the range of concentrations tested (0.25 to 256 ,ug/ml for azlocillin and 0.25 to 16 ,ug/ml for cefotaxime and tobramycin).
The susceptibilities of the study strains to the individual antibiotics are shown in Table 1 . MICs for the various species were similar to those previously reported (4, 14) and fit into the readily definable categories shown. The spectrum of azlocillin was complemented by the 
spectrums of both cefotaxime and tobramycin.
The interactions of azlocillin with cefotaxime or tobramycin are shown in Table 2 . Synergy was consistently present when azlocillin and cefotaxime were tested against S. faecalis and frequently present when azlocillin and tobramycin were tested against P. aeruginosa. Other interactions were usually indifferent or indeterminate. There were no instances of antagonism. In a similar study in which a different medium and a lower inoculum were used (14) , azlocillincefotaxime and azlocillin-amikacin combinations also showed varying frequencies and degrees of synergy against Enterobacteriaceae, P. aeruginosa, and S. aureus. Antagonism with azlocillin-cefotaxime was observed with 11% of the Enterobacteriaceae. [10] [11] [12] 14) . Although antagonism was not observed in the present study, it has been occasionally observed with both types of combinations against Enterobacteriaceae and P. aeruginosa (3, 5, 6, 8, 11, 14) .
I thank Charlotte A. Wright for technical assistance. This study was supported by a grant from Miles Pharmaceuticals.
LITERATURE CITED

